HIV Treatment
Sangamo HIV Gene Therapy Trials: Until There's A Functional Cure, Treatment!
- Details
- Category: Search for a Cure
- Published on Tuesday, 17 January 2012 00:00
- Written by Matt Sharp
Signaling significant progress for research into a functional cure for HIV, Sangamo BioSciences in Richmond, Calif., has announced the start of 2 new clinical trials using SB-728-T, its HIV zinc finger gene therapy technology. Sangamo is the company furthest along in gene therapy for HIV disease.
Top 10 HIV and Hepatitis Stories of 2011
- Details
- Category: HIV Treatment
- Published on Tuesday, 27 December 2011 00:00
- Written by Liz Highleyman
In our last issue for 2011, HIVandHepatitis.com reviews some the year's major news highlights. HIV prevention garnered the most headlines, with studies showing that antiretroviral therapy (ART) prevents transmission and pre-exposure prophylaxis (PrEP) works -- at least for some people some of the time. On the hepatitis C front, the first new direct-acting antiviral drugs were approved, ushering in a new era of more effective treatment.
Immediate ART during Early HIV Infection May Delay Disease Progression
- Details
- Category: HIV Treatment
- Published on Friday, 16 December 2011 00:00
- Written by Liz Highleyman
People who started combination antiretroviral therapy (ART) within 6 months of HIV infection were less likely to experience large CD4 cell decreases or AIDS-related illnesses during follow-up, although viral load set point could not be evaluated, researchers reported in the December 15, 2011 Journal of Infectious Diseases.
HIV Persistence Workshop Highlights Progress Towards a Cure
- Details
- Category: Search for a Cure
- Published on Friday, 16 December 2011 00:00
- Written by Press Release
Researchers meeting this month at the International Workshop on HIV Persistence, Reservoirs and Eradication Strategies in St Maarten presented data from numerous studies looking at various approaches to curing HIV. Some strategies aim to flush latent virus out of hiding, while others are designed to boost immune response. Although the conference largely focused on laboratory and animal research, some early studies in humans were also discussed.
Elvitegravir Continues to Look Good at 2 Years
- Details
- Category: HIV Treatment
- Published on Tuesday, 13 December 2011 00:00
- Written by Press Release
Gilead Sciences announced last week that its experimental integrase inhibitor elvitegravir continued to suppress HIV viral load as well as raltegravir (Isentress) in combination with a boosted protease inhibitor at 96 weeks in a Phase 3 study.
Web Design and Development by